

## **Trendlines Completes Sale of BioSight with 71% IRR**

MISGAV, Israel, 16 June, 2017 -- The Trendlines Group ("**the Group**") (SGX: 42T; OTCQX: TRNLY), a leading Israeli investment and innovation commercialization company, focused on early-stage, high growth innovation-based medical and agricultural technologies, announced the completion of the sale of its BioSight Ltd. ("**BioSight**") shares to Arkin Bio Ventures Limited Partnership on 15 June 2017.

With the completion of the transaction, the Group has sold its entire shareholding in BioSight, receiving pretax proceeds of approximately US\$1.3 million, and approximately US\$1.0 million after tax. Proceeds from the BioSight exit will serve to further strengthen the Group's cash position.

BioSight developed a technology and pipeline of cancer drugs that target and release therapeutic drugs inside cancer cells to reduce systemic toxicity associated with conventional chemotherapy treatments.

Commenting on the exit from BioSight, Trendlines Chairman and CEO, Steve Rhodes said, "This is our second exit in less than 12 months and our first exit of 2017; it yielded a 71% internal rate of return (IRR) for the Trendlines Group. The weighted average IRR of all seven exits completed by the Trendlines Group to date is higher at 101%."

### **About Trendlines**

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfil its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX International (OTCQX: TRNLY).

The Trendlines Group Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release. This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release. The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.

**Investor Contact Information**

Israel: Judith Kleinman, Director Investor Relations & Corporate Communications  
The Trendlines Group  
judith@trendlines.com  
Tel: +972.72.260.7000

Singapore: Reyna MEI  
Financial PR  
reyna@financialpr.com.sg  
Tel: +65.6438.2990

---

Issuer/Manager THE TRENDLINES GROUP LTD.

---

Securities THE TRENDLINES GROUP LTD. – IL0011328858 – 42T

---

Stapled Security No

---

---

Announcement Title General Announcement

---

Date & Time of Broadcast 16 Jun 2017 07:22:57

---

Status New

---

Announcement Sub Title Press Release Trendlines Completes Sale of BioSight

---

Announcement Reference SG170616OTHR8ITN

---

Submitted By (Co./Ind. Name) Yosef Ron

---

Designation Joint Company Secretary

---